How Analysts Rated Invuity, Inc. (NASDAQ:IVTY) Last Week?

September 30, 2018 - By Margaret Guttierez

Invuity, Inc. (NASDAQ:IVTY) Logo

Invuity, Inc. (NASDAQ:IVTY) Ratings Coverage

Among 3 analysts covering Invuity (NASDAQ:IVTY), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Invuity had 3 analyst reports since May 4, 2018 according to SRatingsIntel. Northland Capital downgraded Invuity, Inc. (NASDAQ:IVTY) on Monday, September 17 to “Market Perform” rating. Stifel Nicolaus maintained Invuity, Inc. (NASDAQ:IVTY) rating on Friday, May 4. Stifel Nicolaus has “Buy” rating and $5 target. The stock of Invuity, Inc. (NASDAQ:IVTY) has “Market Perform” rating given on Wednesday, September 12 by Leerink Swann. Below is a list of Invuity, Inc. (NASDAQ:IVTY) latest ratings and price target changes.

17/09/2018 Broker: Northland Capital Old Rating: Outperform New Rating: Market Perform Downgrade
12/09/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Market Perform Downgrade
04/05/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $6 New Target: $5 Maintain

It closed at $7.4 lastly. It is down 11.14% since September 30, 2017 and is downtrending. It has underperformed by 26.76% the S&P500.

Invuity, Inc., a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company has market cap of $178.23 million. The firm integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges. It currently has negative earnings. It offers various illuminated surgical devices, including Eikon LT Illuminated and Eikon illuminated retractor systems for breast oncology/oncoplastic/general/orthopedics surgeries; Saber Yankauer, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general surgeries; and Saber Frazier, a handheld illuminator for spine/orthopedic/neurosurgery surgeries.

More recent Invuity, Inc. (NASDAQ:IVTY) news were published by: Prnewswire.com which released: “Invuity (IVTY) Alert: Johnson Fistel Investigates Proposed Sale of Invuity, Inc.; Is $ $7.40 a Fair Price?” on September 11, 2018. Also Seekingalpha.com published the news titled: “Stryker to acquire Invuity for $7.40/share” on September 11, 2018. Prnewswire.com‘s news article titled: “WeissLaw LLP Investigates Invuity, Inc. Acquisition” with publication date: September 20, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: